Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valneva wants short-term travel, too, for JE vaccine Ixiaro

This article was originally published in Scrip

Executive Summary

While a US federal panel last week unanimously backed the use of Valneva's Ixiaro in youngsters and adolescents to protect against Japanese encephalitis (JE), which can be deadly, the committee's recommendation was limited, with the experts declaring the vaccine need not be considered for short-term travelers whose visits will be restricted to urban areas of countries in which the mosquito-borne flavivirus is endemic or times outside of a well-defined transmission season.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC021860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel